- Home
- NERV vs SMTK Comparison
NERV vs SMTK Comparison
Compare NERV & SMTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- SMTK
- Stock Information
- Founded
- NERV 2007
- SMTK 2009
- Country
- NERV United States
- SMTK United Kingdom
- Employees
- NERV N/A
- SMTK N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- SMTK
- Sector
- NERV Health Care
- SMTK
- Exchange
- NERV Nasdaq
- SMTK NYSE
- Market Cap
- NERV 12.4M
- SMTK 13.3M
- IPO Year
- NERV 2014
- SMTK N/A
- Fundamental
- Price
- NERV $1.84
- SMTK $1.34
- Analyst Decision
- NERV Hold
- SMTK
- Analyst Count
- NERV 1
- SMTK 0
- Target Price
- NERV $5.00
- SMTK N/A
- AVG Volume (30 Days)
- NERV 15.2K
- SMTK 98.3K
- Earning Date
- NERV 08-05-2025
- SMTK 05-13-2025
- Dividend Yield
- NERV N/A
- SMTK N/A
- EPS Growth
- NERV N/A
- SMTK N/A
- EPS
- NERV 0.83
- SMTK N/A
- Revenue
- NERV N/A
- SMTK $105,000.00
- Revenue This Year
- NERV N/A
- SMTK N/A
- Revenue Next Year
- NERV N/A
- SMTK N/A
- P/E Ratio
- NERV $2.23
- SMTK N/A
- Revenue Growth
- NERV N/A
- SMTK 854.54
- 52 Week Low
- NERV $1.15
- SMTK $1.00
- 52 Week High
- NERV $3.69
- SMTK $8.16
- Technical
- Relative Strength Index (RSI)
- NERV 65.83
- SMTK N/A
- Support Level
- NERV $1.75
- SMTK N/A
- Resistance Level
- NERV $1.90
- SMTK N/A
- Average True Range (ATR)
- NERV 0.12
- SMTK 0.00
- MACD
- NERV 0.04
- SMTK 0.00
- Stochastic Oscillator
- NERV 90.00
- SMTK 0.00
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.